Invokana is the top drug advertising in medical journals in 2013
Invokana, which launched earlier this year and treats type 2 Diabetes, is the top drug product advertised in medical journals by both pages and dollars in 2013. This product comprises about 3% of the total share among all drugs. Xarelto, which was the top drug advertising in 2012, ranked second at year-end. It has about 2% of the total share.
Top 5 Print Ad Drugs (Dollars): Jan. – December 2013
- Invokana – $16 MM (N/A)
- Xarelto Tablets - $13 MM (+14%)
- Linzess Capsules – $7 MM (N/A)
- Tudorza Pressair Inhalation Powder– $6 MM (N/A)
- Brilinta Ticagrelor Tablets – $6 MM (+72%)
The percentage changes compare January – December 2013 to that same time period in 2012. For more information on these ad insights or other data, let one of us know.
Kantar Media sets the standard for accurate, comprehensive competitive advertising intelligence in the professional healthcare arena. Check back next month for updated data on the top products, classes, companies and category movers year-to-date.